Date: 2016-08-29
Type of information: Collaboration agreement
Compound: novel compounds for the treatment of schizophrenia
Company: Saniona (Denmark) Boehringer Ingelheim (Germany)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: collaboration
Action mechanism:
Disease: schizophrenia
Details: * On August 29, 2016, Boehringer Ingelheim and Saniona announced that they have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia.
The joint research activities aim to identify compounds that could be capable of restoring brain network activity in patients with schizophrenia. The neuronal activity in the brain of such patients can be impaired by a functional imbalance between stimulating (excitatory) and inhibitory transmission of signals between neurons. The program aligns with Boehringer Ingelheim’s drug discovery strategy for neuropsychiatric diseases which focuses on systematically investigating dominant symptom domains and the underlying neurobiology across mental disorders such as schizophrenia, Alzheimer’s disease and depression. Saniona grants Boehringer Ingelheim exclusive worldwide rights to research, develop, manufacture and commercialise medicines identified through the collaboration.
Financial terms: Saniona will receive an upfront payment of €5 million upon signing of the agreement and milestone payments of up to €50 million upon the achievement of certain research, development and regulatory milestones. In addition, Saniona is entitled to commercial milestone payments of up to €35 million and tiered royalties on net sales of any potential products commercialised by Boehringer Ingelheim as a result of this collaboration. Further financial details were not disclosed. Saniona may receive up to €90 million in milestone payments.
Latest news:
